Home / NULISA Services

NULISA Proteomics
Ultrasensitive. Multiplexed.

NULISA (Nucleic acid Linked Immuno-Sandwich Assay) delivers fg/mL sensitivity across hundreds of targets simultaneously — enabling detection of low-abundance proteins invisible to standard immunoassays. Five panels covering immunology, neurology, and preclinical research.

Overview Inflammation 250 250-plex Inflammation AQ 250+ AQ Neuro 220 220-plex CNS Disease 120 120-plex Mouse Panel 120 120-plex
Technology Overview

Why NULISA?

NULISA combines dual-antibody sandwich immunoassays with nucleic acid signal amplification — achieving attomolar-range (fg/mL) sensitivity that conventional ELISA and standard multiplex platforms cannot match.

This makes NULISA the platform of choice for detecting low-abundance cytokines, neurological biomarkers, and immune mediators in challenging matrices where proteins are present below the detection threshold of other assays.

The automated ARGO HT instrument workflow delivers highly reproducible results with median CVs <10%, and integrated cloud-based analytics streamline data interpretation.

fg/mL
Attomolar sensitivity — orders of magnitude below standard ELISA
<10%
Median CV — highly reproducible across batches and sites
~12 logs
Dynamic range — captures full spectrum from baseline to disease
5 panels
Immunology, neurology, and preclinical research coverage
Immunology · Oncology
NULISAseq Inflammation Panel 250
250-plex · Human · Relative quantification

The broadest NULISA immunology panel. Simultaneously measures 250 inflammation-related proteins — cytokines, chemokines, growth factors, and immune mediators — with fg/mL sensitivity. Designed for comprehensive immune profiling in clinical, translational, autoimmune, and oncology research.

250 proteins covering the full spectrum of inflammatory biology
fg/mL sensitivity detects cytokines at both baseline and disease states
Cytokines, chemokines, growth factors, and soluble receptors
Ideal for biomarker discovery, disease progression, and therapeutic response monitoring
~12 logs dynamic range — no dilution or segmentation required
Median CVs <10% — highly reproducible
Autoimmune Oncology Infectious Disease Drug Development Biomarker Discovery
Request a Quote →
Panel Specifications
Panel size250 proteins
Sensitivityfg/mL (attomolar)
QuantificationRelative
Dynamic range~12 logs
ReproducibilityMedian CV <10%
SpeciesHuman
Sample typesPlasma, serum, CSF, tissue lysate, cell culture supernatant, aqueous humor
Turnaround2–3 weeks
Absolute Quantification
NULISAseq Inflammation Panel AQ
250+ proteins · Absolute quant for 150+ targets

The most advanced NULISA immunology panel — combining relative profiling across 250+ biomarkers with absolute quantitative values for over 150 key targets in a single run. Built for longitudinal clinical studies, PK/PD, and toxicology where cross-study comparisons require standardized measurements.

250+ proteins profiled simultaneously — same breadth as Inflammation 250
Absolute quantification (pg/mL) for 150+ targets — directly comparable across studies and labs
fg/mL sensitivity for detection in both normal baseline and disease samples
~12 logs dynamic range — no dilution or segmentation required
Median CVs <10% — ideal for multi-site and longitudinal studies
Purpose-built for PK/PD, toxicology, and therapeutic monitoring in clinical cohorts
PK/PD Studies Toxicology Longitudinal Studies Drug Development Precision Medicine
Request a Quote →
Panel Specifications
Panel size250+ proteins
Absolute quant targets150+ biomarkers
Sensitivityfg/mL (attomolar)
QuantificationRelative + Absolute (pg/mL)
Dynamic range~12 logs
ReproducibilityMedian CV <10%
SpeciesHuman
Sample typesPlasma, serum, CSF, tissue lysate, cell culture supernatant, aqueous humor
Turnaround2–3 weeks
AQ vs Inflammation 250 — key difference
The AQ panel adds absolute quantification (pg/mL) for 150+ targets on top of the same relative 250+ protein profiling — enabling direct cross-study comparisons without bridging normalization. Recommended for PK/PD, multi-site trials, and longitudinal cohorts.
Neurology
NULISAseq Neuro 220 Panel
220-plex · Human · Neurological biomarkers

A comprehensive panel purpose-built for neurological research. The Neuro 220 profiles 220 CNS-relevant proteins — including established neurodegeneration biomarkers, neurofilaments, synaptic proteins, neuroinflammatory mediators, and glial markers — with fg/mL sensitivity from CSF and blood.

220 curated neurological proteins in a single run
Covers neurodegeneration, neuroinflammation, synaptic function, and glial biology
Validated in CSF, plasma, and serum — key matrices for CNS biomarker research
Includes key AD biomarkers: Aβ42, Aβ40, pTau181, pTau217, NfL, GFAP
Ideal for Alzheimer's, Parkinson's, ALS, MS, and TBI research
fg/mL sensitivity captures neurological biomarkers at pre-symptomatic levels
Alzheimer's Disease Parkinson's Disease ALS Multiple Sclerosis TBI Neuroinflammation
Request a Quote →
Panel Specifications
Panel size220 proteins
Sensitivityfg/mL (attomolar)
Focus areaNeurology & CNS disease
Key biomarkersAβ42, Aβ40, pTau181, pTau217, NfL, GFAP, α-synuclein
QuantificationRelative
Dynamic range~12 logs
SpeciesHuman
Sample typesPlasma, serum, CSF, tissue lysate, cell culture supernatant, aqueous humor
Turnaround2–3 weeks
Neurology · Focused
NULISAseq CNS Disease Panel 120
120-plex · Human · CNS-focused

A focused CNS panel for targeted neurological research. Profiles 120 key central nervous system proteins with fg/mL sensitivity — a streamlined alternative to the Neuro 220 for studies with defined CNS biology hypotheses, smaller cohorts, or validation work following broader discovery.

120 curated CNS-relevant proteins — validated and focused
fg/mL sensitivity for detection of low-abundance CNS proteins in blood
Covers neurodegeneration, neuroinflammation, and synaptic proteins
Validated in CSF, plasma, and serum
Ideal complement to Neuro 220 for focused hypothesis testing or validation
~12 logs dynamic range and median CVs <10%
Neurodegeneration CNS Biomarkers Alzheimer's Targeted Validation
Request a Quote →
Panel Specifications
Panel size120 proteins
Sensitivityfg/mL (attomolar)
Focus areaCNS disease & neurodegeneration
QuantificationRelative
Dynamic range~12 logs
ReproducibilityMedian CV <10%
SpeciesHuman
Sample typesPlasma, serum, CSF, tissue lysate, cell culture supernatant, aqueous humor
Turnaround2–3 weeks
CNS 120 vs Neuro 220 — how to choose
Choose the Neuro 220 for broad CNS discovery. Choose the CNS Disease Panel 120 for defined hypotheses, smaller cohorts, or validation studies. Contact us — we'll help you select the right panel for your study design.
Preclinical · Mouse & Rat
NULISAseq Mouse Panel 120
120-plex · Mouse + Rat cross-reactive · fg/mL

The only NULISA panel designed for preclinical research. Profiles 120 mouse proteins with fg/mL sensitivity and cross-reactivity with rat samples — enabling both mouse and rat studies on a single validated panel without separate assay development or bridging experiments.

120 mouse proteins measured simultaneously
Cross-reactive with rat samples — no separate rat panel needed
fg/mL sensitivity captures low-abundance preclinical biomarkers
Covers immune, inflammatory, metabolic, and neurological targets
Bridges preclinical mouse/rat studies to human clinical research workflows
Enables translational biomarker strategies across species
Preclinical Research Mouse Models Rat Studies Translational Research Drug Development
Request a Quote →
Panel Specifications
Panel size120 proteins
Sensitivityfg/mL (attomolar)
SpeciesMouse + Rat (cross-reactive)
QuantificationRelative
Dynamic range~12 logs
ReproducibilityMedian CV <10%
Sample typesPlasma, serum, CSF, tissue lysate, cell culture supernatant, aqueous humor
Turnaround2–3 weeks
Best forPreclinical mouse/rat studies, translational research

Panel Comparison

All panels run on the ARGO HT system with fg/mL sensitivity and ~12 logs dynamic range. Median CVs <10%.

Panel Plex Species Quantification Best for
Inflammation 250 250 Human Relative Broad immune profiling, oncology, autoimmune
Inflammation AQ 250+ (AQ: 150+) Human Relative + Absolute PK/PD, longitudinal, multi-site clinical trials
Neuro 220 220 Human Relative Broad CNS discovery — AD, PD, ALS, MS, TBI
CNS Disease 120 120 Human Relative Focused CNS hypothesis testing & validation
Mouse Panel 120 120 Mouse + Rat Relative Preclinical & translational research

Not Sure Which Panel Fits Your Study?

Tell us about your samples, species, and biology — we'll recommend the right panel and get a quote within 24 hours.

Request a Quote →